Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2441 November 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Denosumab		
Initial application — Osteoporosis Applications from any relevant practitioner. Approvals valid without further renewal unless notified. Prerequisites(tick boxes where appropriate) The patient has established osteoporosis History of one significant osteoporotic fracture demonstrated radiologically, with a documented T-Score less than or equal to -2.5, that incorporates BMD measured using dual-energy x-ray absorptiometry (DEXA) History of one significant osteoporotic fracture, demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of logistical, technical or pathophysiological reasons History of two significant osteoporotic fractures demonstrated radiologically or Documented T-Score less than or equal to -3.0 or A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm that incorporates BMD measured using DEXA and Bisphosphonates are contraindicated because the patient's creatinine clearance or eGFR is less than 35 mL/min		
or The patient has experienced at least two symptomatic new fractures or a BMD loss greater than 2% per year, after at least 12 months' continuous therapy with a funded antiresorptive agent Bisphosphonates result in intolerable side effects		
or Intravenous bisphosphonates	s cannot be administered due to logistical or technica	al reasons
Initial application — Hypercalcaemia Applications from any relevant practitioner. Approvals valid without further renewal unless notified. Prerequisites(tick boxes where appropriate) Patient has hypercalcaemia of malignancy and Patient has severe renal impairment		